Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

LONDON and TOKYO, February 4 /PRNewswire/ --

- LiMo Platform and APIs Open Market Access for Technology Vendors and Application Developers

LiMo Foundation(TM), a global consortium of mobile leaders delivering an open handset platform for the whole industry, today announced the on-schedule availability in March 2008 of the first release of the LiMo Platform-the first globally competitive, Linux-based software platform for mobile handsets-together with the immediate public availability of the application programming interface (API) specifications.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080204/CLM031LOGO )

LiMo's technology will be showcased in Booth 8b135, Hall 8 at Mobile World Congress (www.mobileworldcongress.com), February 11-14 in Barcelona.

CALGARY, Canada, February 4 /PRNewswire/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported today that Dr. Kevin Harrington and his research group at The Institute of Cancer Research, London, U.K. published the results of their work testing combination treatment schedules of reovirus and radiation in human and murine tumour cells in vitro and in vivo. The paper, entitled "Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy" appears online in the February 1, 2008 issue of Clinical Cancer Research.

REDMOND, Washington, February 3 /PRNewswire/ --

The combination of Microsoft and Yahoo! will create a more competitive marketplace by establishing a compelling number two competitor for Internet search and online advertising. The alternative scenarios only lead to less competition on the Internet.

Today, Google is the dominant search engine and advertising company on the Web. Google has amassed about 75 percent of paid search revenues worldwide and its share continues to grow. According to published reports, Google currently has more than 65 percent search query share in the U.S. and more than 85 percent in Europe. Microsoft and Yahoo! on the other hand have roughly 30 percent combined in the U.S. and approximately 10 percent combined in Europe.

LONDON, February 1 /PRNewswire/ -- The Disciplinary Committee of the Royal College of Veterinary Surgeons has this week refused an application for restoration to the Register from a former Hertfordshire veterinary surgeon who was struck off a year ago for being unfit to practise.

Miss Lesley Kay, of Cambridge Road, Sawbridgeworth, was removed from the Register in January 2007 following her multiple convictions for drink-driving offences, driving disqualification and four-month imprisonment.

The original hearing was held in December 2006, but adjourned until January 2007 to allow time for Miss Kay, who admitted suffering from alcoholism, to address her personal problems and to satisfy certain conditions that the Committee laid down.

LONDON, February 1 /PRNewswire/ --

Chiltern, the global contract research organization, announced today that it has acquired the business of Drug Development Solutions ('DDS'), a leading Phase 1 unit located at Ninewells Hospital and Medical School, Dundee, Scotland. Ninewells is one of the United Kingdom's major teaching hospitals. The purchase of DDS supplements Chiltern's Clinical Research Unit in Slough near London.

ZURICH, Switzerland, February 1 /PRNewswire/ --

Novelis Europe today announced that it will introduce a magnesium surcharge for all standard and painted aluminium sheet products sold into the distributor, building and industrial markets. Magnesium is a common alloying element used in many aluminium products.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/NOVELISLOGO )

The surcharge is in response to the significant rise in global costs of magnesium and is effective for new orders with delivery after April 1, 2008, if not covered by an existing contractual agreement. The surcharge will be 15 Euros per tonne for every 1% of magnesium in the alloy concerned.

Novelis is the leading supplier of high quality aluminium sheet to the European market.